Compare ADP & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADP | BMY |
|---|---|---|
| Founded | 1949 | 1887 |
| Country | United States | United States |
| Employees | N/A | 32500 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.2B | 113.5B |
| IPO Year | 2005 | N/A |
| Metric | ADP | BMY |
|---|---|---|
| Price | $250.40 | $62.23 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 15 |
| Target Price | ★ $275.57 | $61.73 |
| AVG Volume (30 Days) | 2.2M | ★ 9.8M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | 3.16% | ★ 4.38% |
| EPS Growth | ★ 9.67 | N/A |
| EPS | ★ 8.49 | N/A |
| Revenue | ★ $20,560,900,000.00 | N/A |
| Revenue This Year | $7.08 | N/A |
| Revenue Next Year | $5.69 | N/A |
| P/E Ratio | $28.61 | ★ $17.26 |
| Revenue Growth | ★ 7.07 | N/A |
| 52 Week Low | $188.16 | $42.52 |
| 52 Week High | $315.92 | $62.89 |
| Indicator | ADP | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 60.77 | 64.63 |
| Support Level | $249.50 | $56.46 |
| Resistance Level | $265.75 | $62.39 |
| Average True Range (ATR) | 5.99 | 1.46 |
| MACD | -0.51 | 0.39 |
| Stochastic Oscillator | 58.69 | 90.73 |
Automatic Data Processing, or ADP, is a global, cloud-based human capital management provider offering payroll, compliance, talent management, benefits administration, and retirement services. The firm also provides HR outsourcing services, including PEO offerings, enabling clients to reduce HR overhead. Its broad suite serves customers of all sizes across diverse sectors, and the firm holds large market shares in its core markets. As of fiscal 2025, ADP counts over 1.1 million clients and manages payroll for more than 42 million workers across 140 countries.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.